Current research progress and prospects in neoadjuvant therapy for prostate cancer
10.3760/cma.j.cn112139-20250730-00380
- VernacularTitle:前列腺癌新辅助治疗的研究进展与展望
- Author:
Ning XU
1
;
Mengxin LIU
1
;
Zhibin KE
1
Author Information
1. 福建医科大学附属第一医院 福建医科大学附属第一医院滨海院区 国家区域医疗中心泌尿外科，福州 350005
- Publication Type:Journal Article
- Keywords:
Prostatic neoplasms;
Neoadjuvant therapy;
Treatment efficacy;
Survival prognosis
- From:
Chinese Journal of Surgery
2025;63(12):1075-1081
- CountryChina
- Language:Chinese
-
Abstract:
Prostate cancer is the most prevalent malignant tumor in the urinary and male reproductive systems, with its incidence on the rise. In China, most patients are first diagnosed at an advanced stage, missing the window for surgical intervention. Over the years, there has been a continuous evolution in the exploration of neoadjuvant therapy for prostate cancer. Currently, several neoadjuvant approaches have been established, such as neoadjuvant endocrine therapy based on androgen deprivation therapy, neoadjuvant chemotherapy, and neoadjuvant combination therapy. These therapeutic regimens have been shown to enhance pathological responses, including pathological downstaging rate, thereby offering new hope for patients with high-risk localized and locally advanced prostate cancer. However, it remains to be seen whether these therapies can demonstrate a clear advantage in extending overall survival and metastasis-free survival. Further research is necessary to delve into the efficacy differences and safety concerns of these therapeutic approaches.
